BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 12452049)

  • 21. Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma.
    Hori H; Fujimori T; Fujii S; Ichikawa K; Ohkura Y; Tomita S; Ono Y; Imura J; Kuroda Y
    Dis Colon Rectum; 2005 May; 48(5):938-45. PubMed ID: 15785891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation among expression of E-cadherin, beta-catenin, and cyclin D1 in breast cancers].
    Yang JF; Chen SL; Liu ZH; Zhang Y
    Ai Zheng; 2004 Jul; 23(7):799-802. PubMed ID: 15248915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival.
    Zhou YN; Xu CP; Han B; Li M; Qiao L; Fang DC; Yang JM
    World J Gastroenterol; 2002 Dec; 8(6):987-93. PubMed ID: 12439911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours.
    Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
    J Pathol; 2002 Feb; 196(2):154-62. PubMed ID: 11793366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
    Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.
    Chetty R; Serra S; Asa SL
    Am J Surg Pathol; 2008 Mar; 32(3):413-9. PubMed ID: 18300809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer.
    Ohno T; Aihara R; Kamiyama Y; Mochiki E; Asao T; Kuwano H
    Eur J Cancer; 2006 Jan; 42(2):256-63. PubMed ID: 16356709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between expressions of E-cadherin and alpha-catenin and biological behaviors of human pancreatic cancer.
    Li YJ; Meng YX; Ji XR
    Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):471-7. PubMed ID: 14599963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cadherin-catenin expression in primary colorectal cancer: a survival analysis.
    Hugh TJ; Dillon SA; Taylor BA; Pignatelli M; Poston GJ; Kinsella AR
    Br J Cancer; 1999 Jun; 80(7):1046-51. PubMed ID: 10362114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer.
    Shun CT; Wu MS; Lin JT; Wang HP; Houng RL; Lee WJ; Wang TH; Chuang SM
    Hepatogastroenterology; 1998; 45(22):944-9. PubMed ID: 9755986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. alpha-, beta- and chi-catenin expression in human pancreatic cancer.
    Julkunen K; Mäkinen K; Kärjä V; Kosma VM; Eskelinen M
    Anticancer Res; 2003; 23(6D):5043-7. PubMed ID: 14981965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
    Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
    Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wnt pathway is involved in advanced gastric carcinoma.
    Zhang H; Xue Y
    Hepatogastroenterology; 2008; 55(84):1126-30. PubMed ID: 18705344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours.
    Clavel CE; Nollet F; Berx G; Tejpar S; Nawrocki-Raby B; Kaplan HH; van Roy FM; Birembaut PL
    J Pathol; 2001 May; 194(1):20-6. PubMed ID: 11329137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression.
    Koseki K; Takizawa T; Koike M; Ito M; Nihei Z; Sugihara K
    Cancer; 2000 Aug; 89(4):724-32. PubMed ID: 10951333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation of E-cadherin and beta-catenin expression to pit pattern in colorectal cancer.
    Kojima M; Shiokawa A; Ohike N; Tamegai Y; Kato H; Morohoshi T
    Oncol Rep; 2004 Sep; 12(3):533-8. PubMed ID: 15289833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced alpha-catenin and E-cadherin expression in breast cancer.
    Rimm DL; Sinard JH; Morrow JS
    Lab Invest; 1995 May; 72(5):506-12. PubMed ID: 7745946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
    Richmond PJ; Karayiannakis AJ; Nagafuchi A; Kaisary AV; Pignatelli M
    Cancer Res; 1997 Aug; 57(15):3189-93. PubMed ID: 9242448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of classic cadherins type I in urothelial neoplastic progression.
    Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
    Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.
    Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR
    J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.